Synexa Life Sciences Synexa is a specialist biomarker services provider, offering analytical and advisory services to drug and diagnostic developers focused on the identification, development, analysis and interpretation of biomarkers in clinical trials and diagnostic validation programs. Synexa was founded in 2003 by its current management team and has grown rapidly as biomarkers have become an important decision-making tool in drug development. Today, the company employs 40 scientists, operating from custom-designed lab facilities in Cape Town, South Africa and serving clients from all around the world.   Synexa provides an end-to-end set of biomarker services, including: –Discovery of new biomarkers –Development and validation of biomarker assays –Advice on the optimal selection of biomarkers, taking into account cost and benefit of generating biomarker information –A comprehensive portfolio of biomarker assays, including genetic, soluble, cellular and tissue biomarkers. –Interpretation of results and advice on decisions to be made about the candidate drug   Synexa operates through collaborative, risk-sharing partnerships with clients, aiming to deliver insights that significantly improve the quality of decision-making about a drug at an early stage in its development.    Synexa is ISO15189 and ISO17025 accredited.